Bayer announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending a label extension for Eylea 8 mg ...

The company’s product portfolio is anchored by Eylea, used in treating various eye diseases, and Dupixent, which has shown significant growth potential across multiple indications. In the first ...

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN), a leading biopharmaceutical company with a market capitalization of $62.17 billion, finds itself at a critical juncture as it navigates challenges to its ...

Launched in 2022, the drug has robbed Eylea of its dominance of the market—especially in the U.S. Regeneron also said sales were affected in the period by an 11% sequential decrease in ...

They all had severe disease and a high treatment burden with an average of 10 injections with Eylea (aflibercept), a widely-used VEGF inhibitor sold by Bayer and Regeneron, in the last 12 months.

The company's former top-selling treatment, Eylea, is losing ground to biosimilar competition. Luckily, a next-generation version, Eylea HD, is picking up some of the slack. First-quarter Eylea HD ...

Novartis is launching a head-to-head trial of its experimental brolucizumab therapy for age-related macular degeneration (AMD) against Bayer/Regeneron’s Eylea, the market leader. The TALON trial ...

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up for any (or all) of our 25+ Newsletters. Some states have laws and ethical rules regarding solicitation ...